Table 2 Comparison of AS subjects with respect to treatment type
Anti-TNF treatment(n = 23) | Conventional treatment(n = 32) | p value | |
|---|---|---|---|
BASFI | 3.7 (1.5–7.7) | 3.8 (0.1–8.8) | 0.4 |
BASDAI | 4 (1.3–8.1) | 5.5 (1–9) | 0.08 |
BASRI-hip | 0 (0–4) | 0 (0–2.5) | 0.1 |
BASRI-spine | 7.5 (2–12) | 5.5 (2–12) | 0.09 |
BASMI | 4 (1–9) | 2 (1–9) | 0.003 |
BMD-Lumbar spine (g/cm2) | 1 (0.7–1.6) | 0.9 (0.8–1.4) | 0.3 |
BMD-Femoral neck (g/cm2) | 0.8 (0.6–1) | 0.8 (0.5–1.1) | 0.5 |
IL-6 (pg/mL) | 13 (5–545) | 20 (6–300) | 0.9 |
IFNγ (pg/ml) | 0.002 (0.002–0.03) | 0.002 (0.002–1.96) | 0.6 |
BAP (U/L) | 33 (17–107) | 28 (13–47) | 0.04 |
Vitamin D (nM) | 84 (12–266) | 92 (4–244) | 0.9 |
NTX (nM, bone collagen equivalent) | 78 (52–188) | 83 (64–114) | 0.4 |
TRAP 5 (U/L) | 4 (2.3–5.8) | 3.7 (2.3–6.6) | 0.3 |
hPTH (pg/mL) | 46 (44–130) | 46 (44–170) | 0.8 |
sRANKL (pmol/L) | 284 (103–1598) | 285 (101–956) | 0.5 |
OPG (pg/mL) | 274 (52–1080) | 384 (84–1118) | 0.04 |
sRANKL/OPG | 1.28 (0.2–22.6) | 0.73 (0.14–4.5) | 0.03 |
Sclerostin (pmol/L) | 75 (48–95) | 68 (49–126) | 0.6 |
sFRP1 (ng/mL) | 0.1 (0.1–17) | 0.2 (0.1–0.4) | 0.1 |
DKK1 (pg/mL) | 108 (39–771) | 87 (17–370) | 0.03 |